Dana Haviland

815 total citations
14 papers, 517 citations indexed

About

Dana Haviland is a scholar working on Hepatology, Surgery and Oncology. According to data from OpenAlex, Dana Haviland has authored 14 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hepatology, 9 papers in Surgery and 8 papers in Oncology. Recurrent topics in Dana Haviland's work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Dana Haviland is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Dana Haviland collaborates with scholars based in United States and Netherlands. Dana Haviland's co-authors include William R. Jarnagin, Nancy E. Kemeny, Yuman Fong, Ronald P. DeMatteo, Mithat Gönen, Peter J. Allen, David H. Gültekin, Lawrence H. Schwartz, Marinela Capanu and Jinru Shia and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and Annals of Oncology.

In The Last Decade

Dana Haviland

13 papers receiving 515 citations

Peers

Countries citing papers authored by Dana Haviland

Since Specialization

Citations

This map shows the geographic impact of Dana Haviland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana Haviland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana Haviland more than expected).

Fields of papers citing papers by Dana Haviland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana Haviland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana Haviland. The network helps show where Dana Haviland may publish in the future.

Co-authorship network of co-authors of Dana Haviland

This figure shows the co-authorship network connecting the top 25 collaborators of Dana Haviland. A scholar is included among the top collaborators of Dana Haviland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana Haviland. Dana Haviland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration: multicentre, observational cohort study 2025 ·British journal of surgery ·(unknown), David van Klaveren, (unknown), Roeland F. de Wilde, Marc G. Besselink, Eileen M. O’Reilly, Alessandro Paniccia, Matthew H. G. Katz, Ching‐Wei D. Tzeng, Alice C. Wei, Amer H. Zureikat, Bas Groot Koerkamp, (unknown), Amila O. De Silva, Dana Haviland, (unknown), Quisette P. Janssen, Sarah McIntyre, (unknown), (unknown)	0
2	Should Patients With Cystic Lesions of the Pancreas Undergo Long-term Radiographic Surveillance? 2017 ·Annals of Surgery ·Sharon Lawrence, Marc A. Attiyeh, Kenneth Seier, Mithat Gönen, Mark Schattner, Dana Haviland, Vinod P. Balachandran, T. Peter Kingham, Michael I. D’Angelica, Ronald P. DeMatteo, Murray F. Brennan, William R. Jarnagin, Peter J. Allen	54
3	Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component) 2015 ·Annals of Surgery ·Jordan M. Winter, Wei Jiang, Olca Baştürk, Mari Mino–Kenudson, Zhi Ven Fong, Wei Phin Tan, Harish Lavu, Charles M. Vollmer, Emma E. Furth, Dana Haviland, David S. Klimstra, William R. Jarnagin, Keith D. Lillemoe, Charles J. Yeo, Carlos Fernández‐del Castillo, Peter J. Allen	48
4	Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response 2011 ·Annals of Surgical Oncology ·Adam C. Yopp, Lawrence H. Schwartz, Nancy E. Kemeny, David H. Gültekin, Mithat Gönen, Zubin M. Bamboat, Jinru Shia, Dana Haviland, Michael I. D’Angelica, Yuman Fong, Ronald P. DeMatteo, Peter J. Allen, William R. Jarnagin	66
5	Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results 2011 ·Oncology ·Nancy E. Kemeny, Lawrence H. Schwartz, Mithat Gönen, Adam C. Yopp, David H. Gültekin, Michael I. D’Angelica, Yuman Fong, Dana Haviland, Alexandra N. Gewirtz, Peter J. Allen, William R. Jarnagin	55
6	Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: Does the addition of systemic bevacizumab improve results? 2011 ·Journal of Clinical Oncology ·N. E. Kemeny, (unknown), Mithat Gönen, (unknown), Michael I. D’Angelica, Yuman Fong, Dana Haviland, Alexandra N. Gewirtz, Peter J. Allen, William R. Jarnagin	1
7	Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer 2009 ·Annals of Oncology ·Nancy E. Kemeny, Marinela Capanu, Michael I. D’Angelica, William R. Jarnagin, Dana Haviland, Ronald P. DeMatteo, Yuman Fong	71
8	Response to Neoadjuvant Chemotherapy Does Not Predict Overall Survival for Patients With Synchronous Colorectal Hepatic Metastases 2009 ·Annals of Surgical Oncology ·David Gallagher, Junting Zheng, Marinela Capanu, Dana Haviland, Philip B. Paty, (unknown), Michael I. D’Angelica, Yuman Fong, William R. Jarnagin, Peter J. Allen, Nancy E. Kemeny	58
9	Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival 2009 ·Annals of Oncology ·William R. Jarnagin, Lawrence H. Schwartz, David H. Gültekin, Mithat Gönen, Dana Haviland, Jinru Shia, (unknown), Yuman Fong, Ronald P. DeMatteo, Archie Tse, Leslie H. Blumgart, Nancy E. Kemeny	138
10	A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies 2009 ·Cancer Chemotherapy and Pharmacology ·Archie Tse, Nian Wu, Dina Patel, Dana Haviland, Nancy E. Kemeny	10
11	Survival after resection of liver metastases from colorectal cancer with poor clinical risk factors using adjuvant systemic plus hepatic arterial therapy 2008 ·Journal of Clinical Oncology ·N. E. Kemeny, Marinela Capanu, Yuman Fong, Dana Haviland, William R. Jarnagin, Ronald P. DeMatteo, Michael I. D’Angelica	4
12	Is neoadjuvant (neoadj) treatment necessary prior to liver resection in patients with resectable liver metastases (mets) from colorectal carcinoma (CRC) treated with post-resection hepatic arterial infusion (HAI) plus systemic (SYS) chemotherapy 2007 ·Journal of Clinical Oncology ·Nancy E. Kemeny, Marinela Capanu, Fidel David Huitzil Melendez, Dana Haviland, Yuman Fong, William R. Jarnagin, Leslie H. Blumgart, Ronald P. DeMatteo, (unknown)	6
13	Phase I trial of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) in combination with systemic oxaliplatin (OXAL), fluorouracil (FU) + leucovorin (LV) after resection of hepatic metastases from colorectal cancer 2005 ·Journal of Clinical Oncology ·Nancy E. Kemeny, William R. Jarnagin, Mithat Gönen, Dana Haviland, Michael I. D’Angelica, Leslie H. Blumgart, (unknown), Lawrence H. Schwartz, Yuman Fong	4
14	Hepatic arterial infusion (HAI) therapy in patients with unresectable primary liver cancer: Use of dynamic contrast enhanced MRI to evaluate response 2005 ·Journal of Clinical Oncology ·Michael Danso, William R. Jarnagin, Manickam Muruganandham, Lawrence H. Schwartz, Mithat Gönen, Dana Haviland, Leslie H. Blumgart, Michael I. D’Angelica, Ronald P. DeMatteo, Nancy E. Kemeny	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact